US 11,925,618 B2
Pharmaceutical combination for the treatment of cancer
Owe Orwar, Hovas (SE); Sreesha Srinivasa, Bangalore (IN); and Prabha Mishra, Thane (IN)
Assigned to Piramal Enterprises Limited, Mumbai (IN)
Filed by Piramal Enterprises Limited, Mumbai (IN)
Filed on Dec. 13, 2021, as Appl. No. 17/548,849.
Application 17/548,849 is a continuation of application No. 16/725,601, filed on Dec. 23, 2019, granted, now 11,234,963.
Application 16/725,601 is a continuation of application No. 15/313,543, granted, now 10,555,931, issued on Feb. 11, 2020, previously published as PCT/IB2015/053963, filed on May 27, 2015.
Claims priority of provisional application 62/003,575, filed on May 28, 2014.
Prior Publication US 2022/0168273 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4025 (2006.01); A61K 31/41 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/553 (2006.01); A61K 31/7135 (2006.01); A61K 33/36 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4025 (2013.01) [A61K 31/41 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/553 (2013.01); A61K 31/7135 (2013.01); A61K 33/36 (2013.01); A61K 45/06 (2013.01)] 10 Claims
 
1. A pharmaceutical kit for use in a combination therapy with an antioxidant enzyme inhibitor in the treatment of head and neck cancer, lung cancer, gastrointestinal cancer, blood and/or lymphatic system cancer, or breast cancer, the kit comprising:
1) the cyclin-dependent kinase (CDK) inhibitor voruciclib,
2) the antioxidant enzyme inhibitor, and
3) a package insert,
wherein the package insert comprises instructions for administering voruciclib in combination with the antioxidant enzyme inhibitor for the treatment of head and neck cancer, lung cancer, gastrointestinal cancer, blood and/or lymphatic system cancer, or breast cancer in a subject in need thereof.